Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform.
Valneva today announced the initiation of the Phase 2 Clinical Development for its leading, unique Lyme disease vaccine candidate VLA15.
The clinical trial will be conducted at approximately 35 centers worldwide and will include a total of 150 male and female patients.
Congrats to the VBCF Plant Sciences Facility! Their FFG FuE Infrastrukturförderung application for a multi-sensor and multi-approach high-throughput...
Vienna BioCenter launches a state-of-the-art website that lives up to the innovation and dynamism of this vibrant life science cluster.